行情

DMPI

DMPI

DelMar Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.6395
+0.0595
+10.26%
盘后: 0.6255 -0.014 -2.19% 17:39 02/20 EST
开盘
0.5700
昨收
0.5800
最高
0.6849
最低
0.5600
成交量
114.75万
成交额
--
52周最高
6.29
52周最低
0.4020
市值
729.82万
市盈率(TTM)
-0.3351
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DMPI 新闻

  • 《消费者报告》首次将特斯拉Model 3列为"首选车型"
  • 新浪美股.7小时前
  • 低利率的大背景下 市政债券或成“新贵”
  • 新浪财经-自媒体综合.8小时前
  • 巴以双方解除农产品贸易禁令
  • 新华网.9小时前
  • 联储二号人物给交易员"泼冷水" 这次市场共识又错了?
  • FX168.9小时前

更多

所属板块

控股公司
-0.05%
金融
+0.26%

热门股票

名称
价格
涨跌幅

DMPI 简况

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
展开

Webull提供DelMar Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。